TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily With Respect to Preventing VTE After Bariatric Surgery in Obese Patients
Brief Summary: This pilot study is designed to determine the feasibility of conducting a randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice daily with respect to preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after bariatric surgery in obese patients.


Options:
A: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux
B: Arm Label: Before or control group; Type: N/A; Interventions: Other: standard protocol | Arm Label: After or intervention group; Type: N/A; Interventions: Other: thromboprofylaxis protocol | Intervention Type: OTHER; Name: thromboprofylaxis protocol; Assigned to Arm(s): After or intervention group | Intervention Type: OTHER; Name: standard protocol; Assigned to Arm(s): Before or control group
C: Arm Label: Intervention arm: intermediate-dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Heparin Infusion, Drug: Enoxaparin/Lovenox Intermediate Dose | Arm Label: Control arm: prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin Prophylactic Dose, Drug: Heparin SC | Intervention Type: DRUG; Name: Enoxaparin Prophylactic Dose; Assigned to Arm(s): Control arm: prophylaxis | Intervention Type: DRUG; Name: Heparin Infusion; Assigned to Arm(s): Intervention arm: intermediate-dose anticoagulation | Intervention Type: DRUG; Name: Heparin SC; Assigned to Arm(s): Control arm: prophylaxis | Intervention Type: DRUG; Name: Enoxaparin/Lovenox Intermediate Dose; Assigned to Arm(s): Intervention arm: intermediate-dose anticoagulation
D: Arm Label: Investigational arm; Type: EXPERIMENTAL; Interventions: Drug: Heparin | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Investigational arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure
Brief Summary: This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart failure (CHF) patients hospitalized for an episode of acute decompensated heart failure.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
Brief Summary: This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo of vildagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: placebo of vildagliptin; Assigned to Arm(s): Placebo
D: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DaVita Assessment of Nutritional Supplement Effects
Brief Summary: This is a Phase IV randomized controlled study assessing the effectiveness of a commercially available nutritional supplement on malnourished prevalent hemodialysis patients. Patients will be randomized to either receive one can of Nepro with Carb Steady at each dialysis treatment for 6 months or to receive the standard of care counseling for malnutrition. The primary hypothesis is that hypoalbuminemic maintenance hemodialysis patients will demonstrate an improvement in albumin levels with oral nutritional supplement provided in-center thrice weekly in addition to standard of care as compared to malnourished maintenance hemodialysis patients provided standard of care alone.


Options:
A: Arm Label: Ceprolac; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ceprolac | Arm Label: Dietary counseling (DC); Type: PLACEBO_COMPARATOR; Interventions: Other: Dietary counseling (DC) | Intervention Type: DIETARY_SUPPLEMENT; Name: Ceprolac; Assigned to Arm(s): Ceprolac | Intervention Type: OTHER; Name: Dietary counseling (DC); Assigned to Arm(s): Dietary counseling (DC)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nepro nutritional supplement | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Nepro nutritional supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care | Arm Label: Nepro with Carb Steady; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nepro with Carb Steady | Intervention Type: DIETARY_SUPPLEMENT; Name: Nepro with Carb Steady; Assigned to Arm(s): Nepro with Carb Steady | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: activity group; Type: EXPERIMENTAL; Interventions: Device: Exercise training in addition to nutritional support | Intervention Type: DEVICE; Name: Exercise training in addition to nutritional support; Assigned to Arm(s): activity group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Early Psychological Intervention to Prevent PTSD
Brief Summary: This study will examine the use of prolonged exposure therapy on people who have recently experienced a trauma to prevent them from developing post-traumatic stress disorder.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure (PE) Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure (PE) Therapy; Assigned to Arm(s): 2
B: Arm Label: Discussion with nurse; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ICU Diary; Type: EXPERIMENTAL; Interventions: Other: ICU Diary | Intervention Type: OTHER; Name: ICU Diary; Assigned to Arm(s): ICU Diary
C: Arm Label: Cognitive Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: Placebo comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): Cognitive Behavior Therapy
D: Arm Label: Prolonged Exposure (CBT); Type: EXPERIMENTAL; Interventions: Procedure: Cognitive Behavioral Therapy | Arm Label: Cognitive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive Therapy | Arm Label: SSRI (escitalopram); Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Waiting List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Prolonged Exposure (CBT) | Intervention Type: PROCEDURE; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): SSRI (escitalopram) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Early Psychological Intervention to Prevent PTSD
Brief Summary: This study will examine the use of prolonged exposure therapy on people who have recently experienced a trauma to prevent them from developing post-traumatic stress disorder.


Options:
A: Arm Label: Qigong training; Type: EXPERIMENTAL; Interventions: Behavioral: Qigong training | Arm Label: Wait-list control- Health talks; Type: OTHER; Interventions: Other: Wait-list control- Health talks | Intervention Type: BEHAVIORAL; Name: Qigong training; Assigned to Arm(s): Qigong training | Intervention Type: OTHER; Name: Wait-list control- Health talks; Assigned to Arm(s): Wait-list control- Health talks
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure (PE) Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure (PE) Therapy; Assigned to Arm(s): 2
C: Arm Label: PE-HBT; Type: EXPERIMENTAL; Interventions: Behavioral: PE | Arm Label: PE-SD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PE | Intervention Type: BEHAVIORAL; Name: PE; Assigned to Arm(s): PE-HBT, PE-SD
D: Arm Label: treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment as usual | Arm Label: interpersonal psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy; Assigned to Arm(s): interpersonal psychotherapy | Intervention Type: BEHAVIORAL; Name: treatment as usual; Assigned to Arm(s): treatment as usual

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WEB-based Distress Management Program for Implantable CARdioverter dEfibrillator Patients (WEBCARE) Trial
Brief Summary: The implantable cardioverter defibrillator (ICD) is generally well-accepted by patients, but a subgroup experiences increased anxiety and poor quality of life. A web-based behavioral intervention may comprise a novel approach to reduce anxiety and enhance well-being in ICD patients, which may be equally effective and have advantages over more traditional forms of therapy, due to its low-threshold accessibility via the internet.

The purpose of this study is to determine whether patients receiving a behavioral intervention via the internet experience less anxiety and device concerns and improved quality of life compared to patients receiving usual care.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Stress Management | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Stress Management; Assigned to Arm(s): 2
B: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
C: Arm Label: Web-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web-based multifactorial intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: Behavioral: web-based multifactorial intervention | Intervention Type: BEHAVIORAL; Name: web-based multifactorial intervention; Assigned to Arm(s): Usual care, Web-based behavioral intervention
D: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting
Brief Summary: To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Ondansetron | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): 6
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW679769 (casopitant) | Intervention Type: DRUG; Name: GW679769 (casopitant); Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Intervention Type: DRUG; Name: APD405; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
D: Arm Label: Palonosetron group; Type: N/A; Interventions: N/A | Arm Label: Granisetron group; Type: N/A; Interventions: N/A | Arm Label: Ramosetron group; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.


Options:
A: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Other: Psychosocial intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: Psychosocial intervention | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Psychosocial intervention; Assigned to Arm(s): Methylphenidate, Placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: Citalopram and psychosocial intervention; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Arm Label: Placebo and psychosocial intervention; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): Citalopram and psychosocial intervention | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo and psychosocial intervention
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 100 mg LY450139; Type: EXPERIMENTAL; Interventions: Drug: LY450139 | Arm Label: 140 mg LY450139; Type: EXPERIMENTAL; Interventions: Drug: LY450139 | Intervention Type: DRUG; Name: LY450139; Assigned to Arm(s): 100 mg LY450139, 140 mg LY450139 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.


Options:
A: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Buprenorphine plaster; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine plaster | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Buprenorphine plaster; Assigned to Arm(s): Buprenorphine plaster | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
B: Arm Label: Citalopram and psychosocial intervention; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Arm Label: Placebo and psychosocial intervention; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): Citalopram and psychosocial intervention | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo and psychosocial intervention
C: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
Brief Summary: This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT 003) | Arm Label: GP MDI (PT001); Type: EXPERIMENTAL; Interventions: Drug: GP MDI (PT001) | Arm Label: FF MDI (PT005); Type: EXPERIMENTAL; Interventions: Drug: FF MDI (PT005) | Arm Label: Open-label tiotropium bromide inhalation powder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®) | Intervention Type: DRUG; Name: GFF MDI (PT 003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: GP MDI (PT001); Assigned to Arm(s): GP MDI (PT001) | Intervention Type: DRUG; Name: FF MDI (PT005); Assigned to Arm(s): FF MDI (PT005) | Intervention Type: DRUG; Name: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Assigned to Arm(s): Open-label tiotropium bromide inhalation powder
C: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
D: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to tiotropium | Arm Label: Tiotropium 18 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Indacaterol 150 µg

Answer: D